Europe has a plan to insulate itself from drug shortages, which the U.S. could also benefit from — unless tariffs get in the ...

Based on the reciprocal tariff approach, a 10% tariff on Indian pharma imports could be a possibility, but BofA cites a few ...

In today's Pharmalittle roundup, we're reading about Medicare negotiations, U.K. drug rebates rising, and more.

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV ...

"We do not see headwinds happening in terms of any asset quality on account of tariff related issues," Setty says.

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...

The uptick in the Zydus Life shares came after the company received final approval from the USFDA to manufacture Eluxadoline ...

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Lizzi C. Lee speaks with Gary Rieschel about what's behind China's biotech boom, potential risks, and long-term global ...